Home > Insider Trading > Filing (0001209191-23-044892)

Filing Details

Accession Number:: 0001209191-23-044892
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-08-07 20:50:54
Reporting Period:: 2023-08-03

Accepted Time:: 2023-08-07 20:50:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1746473	Pliant Therapeutics Inc.	PLRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1614876	Hans Hull	C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-08-03	13,069	$20.00	206,114	No	4	S	Direct
Common Stock	Acquisiton	2023-08-03	1,800	$2.08	207,914	No	4	M	Direct
Common Stock	Acquisiton	2023-08-03	1,800	$20.00	206,114	No	4	S	Direct
Common Stock	Acquisiton	2023-08-04	8,791	$2.08	214,905	No	4	M	Direct
Common Stock	Disposition	2023-08-04	20,050	$20.01	194,855	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock (Right to Buy)	Disposition	2023-08-03	1,800	$0.00	1,800	$2.08
Common Stock	Common Stock (Right to Buy)	Disposition	2023-08-04	8,791	$0.00	8,791	$2.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
40,158		2028-03-31	No	4	M	Direct
31,367		2028-03-31	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,821	Indirect	See footnote
Common Stock	13,985	Indirect	See footnote
Common Stock	13,985	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer.